SMT Sahajanand Medical Technologies a pioneering healthcare company in India with a focus on innovative patient care in the cardiovascular sector is pleased to announce promising data from its study the Prospective SFLEX UKII Registry.
Positive six-month clinical data were announced by Elixir Medical during the Transcatheter Cardiovascular Therapeutics (TCT) conference, TCT 2023, in San Francisco, CA today. The DESyne BDS Plus Randomized Controlled Trial (RCT) evaluated DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES).
First head-to-head randomized clinical trial (RCT) of DynamX Bioadaptor compared to Resolute Onyx DES shows statistically significant effectiveness in restoring vessel pulsatility, achieving significantly
Late-breaking clinical data presented at EuroPCR 2023 in Paris demonstrated Elixir Medical’s DynamX Bioadaptor restores vessel motion and function with better effectiveness at 12 months compared to a leading drug-eluting stent (DES).
Spain: Cre8 EVO stents (polymer-free amphilimus-eluting stent) are superior to Resolute Onyx stents (polymer-based zotarolimus-eluting stent) in patients with diabetes undergoing PCI with regard to.